



Supplementary Fig. 3. Proportion of those prescribed sodium-glucose cotransporter 2 inhibitor (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) or accompanied atherosclerotic cardiovascular disease (ASCVD) according to gender, age, and income level in 2019. NS, not significant. ^a*P* < 0.0001.